Analysts Expect Zosano Pharma Corp (NASDAQ:ZSAN) Will Post Earnings of -$0.10 Per Share

Wall Street analysts forecast that Zosano Pharma Corp (NASDAQ:ZSAN) will announce earnings of ($0.10) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Zosano Pharma’s earnings. Zosano Pharma posted earnings of ($0.55) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 81.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 12th.

According to Zacks, analysts expect that Zosano Pharma will report full year earnings of ($0.50) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($0.20) per share. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Zosano Pharma.

Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04.

Several equities research analysts have issued reports on ZSAN shares. ValuEngine upgraded shares of Zosano Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. BTIG Research decreased their price objective on shares of Zosano Pharma from $16.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, March 27th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Zosano Pharma in a research note on Friday, May 15th. Maxim Group reiterated a “buy” rating on shares of Zosano Pharma in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of Zosano Pharma from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Saturday. Six research analysts have rated the stock with a buy rating, Zosano Pharma presently has a consensus rating of “Buy” and a consensus target price of $4.00.

Several hedge funds have recently made changes to their positions in the company. UBS Group AG boosted its stake in Zosano Pharma by 45.8% during the 1st quarter. UBS Group AG now owns 99,932 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 31,375 shares during the last quarter. Oxford Asset Management LLP bought a new position in Zosano Pharma during the 4th quarter valued at $57,000. Ieq Capital LLC bought a new position in Zosano Pharma during the 4th quarter valued at $79,000. Sabby Management LLC bought a new position in Zosano Pharma during the 1st quarter valued at $114,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. bought a new position in Zosano Pharma during the 4th quarter valued at $182,000. Institutional investors and hedge funds own 12.45% of the company’s stock.

ZSAN stock remained flat at $$0.85 on Friday. 761,694 shares of the company traded hands, compared to its average volume of 1,678,598. Zosano Pharma has a 1 year low of $0.41 and a 1 year high of $3.54. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.93 and a quick ratio of 0.93. The company has a fifty day simple moving average of $0.71 and a two-hundred day simple moving average of $1.12. The firm has a market cap of $46.20 million, a PE ratio of -0.47 and a beta of 2.63.

Zosano Pharma Company Profile

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

See Also: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.